Vincristine sulfate

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。

规格 价格 库存 购买数量  
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献14篇:

客户使用该产品的5个实验数据:

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    Determination of mutation frequencies in cells treated with chemotherapy drugs following caspase inhibition. TK6 cells were incubated with no inhibitor or 10 μM QVD then treated with the following drug doses: 300 ng/ml TRAIL, 0.7 μM cisplatin, 0.5 μM temozolomide, 3 nM doxorubicin, 0.5 nM SN38 or 0.07 nM vincristine. (a) Caspase activity was assessed by luminescent detection of Caspase-3/-7 Glo reagent after 5 h. After 24- h treatment, (b) clonogenicity assays were performed to determine the proportion of cells maintaining clonogenic competency after treatment, whereas (c) surviving cells were grown in 6TG to select for the emergence of any HPRT mutants. (d) Clonogenicity and (e) HPRT mutation assays were repeated in CASP3/7 DKO lines in the same manner. Error bars represent mean±S.E.M. from at least three independent experiments. Two-sided T-tests were used to calculate P-values.

    Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454. Vincristine sulfate purchased from Selleck.

  • Discrimination of micronuclei induced by EMS and VCR in V79-hCYP2E1-hSULT1A1 cells as CENP-B negative or positive. The cells were treated with EMS (5 mM) or VCR (5 nM) for 6 h, followed by a recovery period of 18 h. They were stained for CENP-B (green) and β-tubulin (red) by the immunofluorescence assays, as described in Section 2.5. DNA was stained with DAPI (blue). The vertical and horizontal arrows indicate CENP-B-negative and CENP-B-positive micronuclei, respectively.

    Chemosphere, 2018, 210:467-475. Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

  • c Quantification of surviving colony numbers from clonogenic assays of D283 Med cells exposed to 10, 20, or 40 μM lomustine with or without 10 nM E2 (n = 6 for each group). d Quantification of colony number from clonogenic assays of D283 Med cells exposed to 5, 10, or 20 nM vincristine with or without 10 nM E2 (n = 8 for each group). All results are expressed as mean ± SEM. Significant differences from the control group were determined by two-way ANOVA followed by Holm-Sidak’s post-test analysis and is indicated above the error bars; * p ≤ .05

    BMC Pharmacol Toxicol, 2017, 18(1):63. Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NH;hOYVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEf2VXUxNTBwNTFOwG0> NEjyfY0zPCCq M3TKbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWPnc2x7OjV4NkO3Olk>
HepG2-HBV1.1 NHq5e41CeG:ydH;zbZMhSXO|YYm= MnLYNE0xNjVizszN MoLLNlQhcA>? NVLiSpZKcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NGG5W5MzPTZ4M{e2PS=>
HepG2.2.15 NFSxcHJHfW6ldHnvckBCe3OjeR?= MorNNE4yKM7:TR?= Mn74NlQhcA>? Mn7RdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u M3zPSFI2PjZ|N{[5
HepG2-HBV1.1 NH:1NHBHfW6ldHnvckBCe3OjeR?= NX7udnp1OC5zIN88US=> NICzUXUzPCCq MYLwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NF\ibFUzPTZ4M{e2PS=>
HepG2-HBV1.1 MYnGeY5kfGmxbjDBd5NigQ>? NVXMSpptOC5zIN88US=> MX20PEBp MW\wdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> MWCyOVY3Ozd4OR?=
HepG2-HBV1.1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0R|ZUOC5zIN88US=> NUS0UJVNOS13IHS= M1;2WIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= MkLWNlU3PjN5Nkm=
HepG2-HBV1.1 NUPH[HE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\1dZdmOC5zIN88US=> MoG3NU02KGR? MYDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 NX7Qc21XOjV4NkO3Olk>
HepG2-HBV1.1 M3L6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P1TlAvOSEQvF2= M2m1TVEzNTd{IHi= NFHIcpBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> NFztRZMzPTZ4M{e2PS=>
HepG2-HBV1.1 NEDCb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lNE4yKM7:TR?= MVixNk04OiCq MVvpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= NUDoXYl1OjV4NkO3Olk>
Raji M2ruXmZ2dmO2aX;uJGF{e2G7 MlnVNE42yqEQvF2= Ml3uO|IhcA>? NFvKT5Vi[m:uaYPo[ZMh[XW2b4DoZYd6yqB? NUjKcnFGOjV2NE[zO|c>
SK-MEL-28  MmfJSpVv[3Srb36gRZN{[Xl? M{XNTlMxKG6P M1fXN|YhcA>? MlvYbY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? NFXnT4YzPTNzM{CxNC=>
H157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fKXWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP MnXONlUzPTd7MUG=
Jurkat M1rINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;iPIhPOS1|IH7N MoTUOFjDqGh? NYHFUGpSTE2VTx?= MnTW[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> M4\pOlI2OTV4MUS2
CEM M1v2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexMVMhdk1? MmOxOFjDqGh? NWnvSFA2TE2VTx?= NFjCUZNl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 NHnKZpczPTF3NkG0Oi=>
P12 M3[1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;oNlIyNTNibl2= NXznNIM1PDkEoHi= M1;wS2ROW09? M1H5eIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MWqyOVE2PjF2Nh?=
KB M2noZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fOVWlEPTB;MD6wNFQ6KMLzIECuNFAxOSEQvF2= M2\pdFI2ODV6NUK2
KBv200 (ABCB1) MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwM{S2NkDDuSByLkCwOlYh|ryP M{\YblI2ODV6NUK2
SUDHL6  M{Xqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOzWFIy6oDLzszN M3yzS|Q5Nzd{IHi= Mnu0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NFSxd4QzPDl4MU[wOC=>
SUDHL6  NELBc3BHfW6ldHnvckBCe3OjeR?= NIPEe|Qy6oDLzszN NWTNdFg2PzJiaB?= Mm\ubY5lfWOnczDzbYdvcW[rY3HueEBieG:ydH;0bYMhdW:{cHjvcI9ogSClaHHu[4V{KGOxdILld5Rm\CC5aYToJGJEVDFzQTDzbXJPSQ>? MWSyOFk3OTZyNB?=
HCT-116 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XKWWdKPTB;NTDuUS=> NYTvOHpiOjR7Mke4OVc>
SKNBe2C MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnUdoNkUUN3ME2zNk45yrF2LkCgcm0> NWC3[GozOjR7MkG5NlA>
IGNR91 M1OxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DnSmlEPTB;MkSuN:KyOS55IH7N M1;0b|I1QTJzOUKw
SKNAS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKwTWM2OD1zLkZCtVAvOiCwTR?= NI\uPGwzPDl{MUmyNC=>
LAN1 NUDhPYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nZN2lEPTB;Mj6zxtExNjJibl2= Ml\PNlQ6OjF7MkC=
SHSY5Y M3vBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPoTWM2OD16LkNCtVAvPiCwTR?= M1raW|I1QTJzOUKw
A549-WT MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDpTWM2OD1zOT60N|chyrFiMD61PVQhKG6P MVyyOFg2QDh{Nx?=
A549-R MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MVWyOFg2QDh{Nx?=
MCF-7-WT M13JR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G1OWlEPTB;MUeuO|UzKMLzIECuNlE5KCCwTR?= NXr5fWliOjR6NUi4Nlc>
MCF-7-R NHTlenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPGfYtMUUN3ME21MlU{QSEEsTCwMlE1PCBibl2= NYC3fXZSOjR6NUi4Nlc>
A549-R NFLEZm1EgXSxdH;4bYNqfHliQYPzZZk> M3WzR2lEPTB;MUKuNVc5KMLzIECuN|M{KG6P NInjT4szPDh3OEiyOy=>
MCF-7-R MnnjR5l1d3SxeHnjbZR6KEG|c3H5 NGWxWo9KSzVyPUWuOVM6KMLzIECuNVQ1KG6P NVW2[pF3OjR6NUi4Nlc>
SW620 NYHTXZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXVHRQUUN3ME23MlgxKMLzIECuNFghdk1? M{Gy[|I1PzJ4N{O5
SW620/AD300 NHWzWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHyTWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? MmDhNlQ4OjZ5M{m=
HEK293/pcDNA3.1 M2HV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLdmtKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? NHO1N28zPDd{NkezPS=>
HEK293/ABCC1 NXLFSoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{POVWlEPTB;MUmuNlkhyrFiMj6wPEBvVQ>? NXfkTZp7OjR5Mk[3N|k>
TCC MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[yOEBp NFzOUZdKSzVyPUewJI5O MXiyOFcyPjl2NB?=
TCC MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO0PEBp M4\KcmlEPTB;NUCgcm0> Mor0NlQ4OTZ7NES=
HepG2/ADM Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? NXjYXmZuOjR5MES1OVY>
HepG2 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUemxKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= NVHaZmdyOjR5MES1OVY>
MCF-7/ADR MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwNEiyOuKyOC5{MEewJO69VQ>? M1\pV|I1PzB2NUW2
MCF-7 M{XP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[zbZhMUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= NWfmZWYxOjR5MES1OVY>
A-172  NHXjPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnWcnlJOC5zwrFOwG0> Mn\CNlQwPzJiaB?= NULPc3Z3cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MnK1NlQ2OzB{M{W=
U-251MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MleyNE4yyqEQvF2= NHy5NmEzPC95MjDo M{fIOIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NGm2eoMzPDV|MEKzOS=>
DLD-1 MYPGeY5kfGmxbjDBd5NigQ>? MVyxNFAhdk1? M{mwS|Q5KGh? MYrwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NED1dmkzPDRyM{S1Ny=>
CCD18Co MorxSpVv[3Srb36gRZN{[Xl? NFTzTowyODBibl2= NH\SR5c1QCCq MnjHdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NYDkTlBPOjR2MEO0OVM>
DLD-1 NH;uW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi3OJRGOC1zMECwJI5O M3XTOVQ5KGh? M{XtNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXPBUIx{OjR2MEO0OVM>
CCD18Co NILWfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\DdZE4OC1zMECwJI5O NXi2TI91PDhiaB?= Mle2bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mne2NlQ1ODN2NUO=
HepG2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvubXZwOjRiaB?= NYX2Vmd1UUN3ME21Nk426oDLzszN MWWyOFM1OTZ6OB?=
HEK293/pcDNA3.1 NHLvcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHCTWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? NXr3RZZUOjR{OES3PFM>
HEK293/MRP1 M{fHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6xToU6UUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= NUTNSY9qOjR{OES3PFM>
Ramos NWjOWZhNSXCxcITvd4l{KEG|c3H5 MXSy5qCK|ryP NG[2WJE1QCCq MXrpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> MUSyOFI2PjR7MR?=
NCI-H1299/pcDNA3 M4XZRWNmdGxiVnnhZoltcXS7IFHzd4F6 NEDGSlUxNTJyIH7N NULWOVJvQTZiaB?= MV3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NIq3SFkzPDF5N{CxNi=>
H1299/ICAM-3 NGnKdlBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{e0T|AuOjBibl2= MV[5OkBp MmDUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXzCZ3dqOjRzN{ewNVI>
NCI-H1299/pcDNA3 MYjGeY5kfGmxbjDBd5NigQ>? MlzUNU82NzFyL{KwxsBvVQ>? NH\wUnk6PiCq NVvmWWwzcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? NH;6bFUzPDF5N{CxNi=>
H1299/ICAM-3 MmTUSpVv[3Srb36gRZN{[Xl? MVmxM|UwOTBxMkFCpI5O M3XiVFk3KGh? MXvpcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ Mlj4NlQyPzdyMUK=
W1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Lw[GlEPTB;MD6wNFMzKM7:TR?= NYXpRVRbOjRzNECxO|Y>
W1VR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH0c5VKSzVyPUCuNFU3KM7:TR?= MVqyOFE1ODF5Nh?=
K562 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTUTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP M4jncFI1OTN3OUO3
K562/ADR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfZWlMzUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NEnybYEzPDF|NUmzOy=>
K562 NEe0eoRCeG:ydH;zbZMhSXO|YYm= NVr3bYFDOC5|IN88US=> NEGyfXIzPCCq MlXJbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NUnpdppwOjRzM{W5N|c>
K562/ADR MUDBdI9xfG:|aYOgRZN{[Xl? NVLqb3A6OyEQvF2= NITsRpUzPCCq MYTpcoR2[2W|IHHwc5B1d3Orcx?= NIPqcnYzPDF|NUmzOy=>
A549 M33Fbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUCgxtEhOC5yMzFOwG0> NGLBTZIzOzl5MUC3OS=>
K562 NUTnOmU3S2WubDDWbYFjcWyrdImgRZN{[Xl? M{HGVFMvPzYkgKO2NOKhdk1? NWjKb3NOPzMEoHlCpC=> NYXLbo1wcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3\kO|I{QDd5MkKz
lucena MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmGxN{44PeLCk{[wxsBvVQ>? MWS3NuKhcMLi NITKb2dvdyCnZn\lZ5Q> NFPpXpYzOzh5N{KyNy=>
FEPS M1LTUmNmdGxiVnnhZoltcXS7IFHzd4F6 MkjpN{44PeLCk{[wxsBvVQ>? NH;rd4k4OsLiaNMg MV3uc{Bm\m[nY4S= NWL1NZg4OjN6N{eyNlM>
A2780 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHaTWM2OD1|LkWgcW0> M3vtTlI{QDJ7MkCz
ACHN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDCV4xWUUN3MEywMlEhdU1? NH7ETFQzOzh{OUKwNy=>
U-937 NVz5dVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRDN2IH7N M2HvTVI{QDJ7MkCz
Jurkat MWDBdI9xfG:|aYOgRZN{[Xl? MmXqOeKh|rypL33sxsA> MVGyOEBp M3nwRYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MmP3NlM5OTB2MEm=
Jurkat M1\MU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[0dJptPcLizsznM41tyqB? NFLEZ|EzPCCq MXfhdpJme3RiSoXyb4F1KGOnbHzzJIlvKEd{L12gdIhie2V? MXyyN|gyODRyOR?=
Hep-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHxZ5BKSzVyPUCuNFTDuTBwMEGg{txO MkDyNlM4QDB2MkS=
Hep-2/v MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDpc5pKSzVyPUGuPOKyOC5{MDFOwG0> MUWyN|c5ODR{NB?=
SGC-7901 M4PCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrQUmg5OC1zMDFOwIcwdWx? M3H5TlI1NzR6L{eyJIg> MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M2W1SFI{PzR|NUey
SGC-7901/VCR MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\6OlAuOTBizsznM41t NX\IXmdSOjRxNEivO|IhcA>? NInkblNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NXOzSYNVOjN5NEO1O|I>
SGC-7901 Mn[zRZBweHSxc3nzJGF{e2G7 MmLlbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MVuyN|c1OzV5Mh?=
SGC-7901/VCR M{LyUmFxd3C2b4Ppd{BCe3OjeR?= MmfxbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NInNbIozOzd2M{W3Ni=>
KB-3-1 M1jlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nnZ2lEPTB;MT62OkDDuSByLkG2NkDPxE1? MWiyN|Y4OzR2NR?=
KB-C2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4TYRoUUN3ME2yNFIvPTZiwsGgOFIvPDhzIN88US=> M2q5RlI{Pjd|NES1
KB-3-1 NYfv[XNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPKcJRKSzVyPUGuNlYhyrFiMD6wNlch|ryP MUSyN|Y4OzR2NR?=
KB-V1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n3OGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP M3GySVI{Pjd|NES1
HEK293/pcDNA3.1 NFXzfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ2LkGgxtEhOC5{MESg{txO M4HNc|I{Pjd|NES1
HEK293/ABCB1 NGe5WJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfGfHNKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> MUKyN|Y4OzR2NR?=
A549/EGFP  NGnQemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW1XlcxNjBzLUGwNFAh|ryP NHXC[IVKSzVyPUi2MlchyrFiMkmuNUDPxE1? MWiyN|Y{PDJ6Mh?=
A549/Slug MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL3[nAxNjBzLUGwNFAh|ryP Mnj5TWM2OD17LkegxtEhOy5zIN88US=> NXThTY9EOjN4M{SyPFI>
JFCR39  M{Wy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xJOK2VQ>? M1PGdlI1KGh? NH33So5FVVOR M{fKO41iemunZHz5JIlv[3KnYYPld{B1cGViboXtZoVzKG:oIFeyM20heGijc3WgZ4VtdHN? M{nTOlI{PTl6Mke2
A549 NX\NcIczTnWwY4Tpc44hSXO|YYm= MVGxNFAhdk1? NGrOUXcyPiCq M1;te2ROW09? NF:yV4Jt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| M2PQN|I{PTl6Mke2
SGC7901 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XSTWlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> MVKyN|U3PDR6Mh?=
SGC7901/LV-NC NE\OfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwN{hihKnDueLCiUCuNVYh|rypL33s MWGyN|U3PDR6Mh?=
SGC7901/LV-SGO1 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED5[4lKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t NXrTXVJzOjN3NkS0PFI>
SGC7901/VCR NVvObJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|U{RTJyLkWz5qCKyrIkgJmxMlk3KM7:Zz;tcC=> MlLtNlM2PjR2OEK=
SGC7901/VCR-NC NWPpT5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=> M2fnZ|I{PTZ2NEiy
SGC7901/VCR-si-SGO1 NXftUXhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfmTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> M2D0ZVI{PTZ2NEiy
SGC7901/ADR NWDIUXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruSm12UUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? M1zpe|I{PTZ2NEiy
SGC7901/ADR-NC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s MUCyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 NWPvZpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwNEdihKnDueLCiUCuNlkh|rypL33s MlXyNlM2PjR2OEK=
SH-SY5Y  M4[wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlAxOS1zMDFOwG0> MVSyOEBp NH\pNoZKSzVyPUCuNVE{yrFyLkCxNkDPxE1? MmjqNlMyOjlyNkW=
SH-SY5Y  M3\r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7oRmQxNjByMT2xNEDPxE1? NGDzN|I1QCCq MVLJR|UxRTBwMEe4xtExNjByOTFOwG0> NFTnU2EzOzF{OUC2OS=>
SH-SY5Y  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TzWVAvODBzLUGwJO69VQ>? NFHyfIo4OiCq MorNTWM2OD1yLkC1NeKyOC5yMEig{txO M1fBd|I{OTJ7ME[1
SH-SY5Y NHP1WJNCeG:ydH;zbZMhSXO|YYm= MX[wMlEh|ryP M4LLXVAuOjRiaB?= NYDkUWdrcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> NYO0UXdyOjNzMkmwOlU>
SH-SY5Y MUXBdI9xfG:|aYOgRZN{[Xl? NV7S[ndNOC5zIN88US=> Moe4NE0zPCCq NHrtV5NqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= M{Pzd|I{OTJ7ME[1

... Click to View More Cell Line Experimental Data

体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Formulation: 水溶液
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
稳定性 powder
in solvent
别名 Leurocristine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03871257 Not yet recruiting Low Grade Glioma|Neurofibromatosis Type 1|Visual Pathway Glioma National Cancer Institute (NCI) May 3 2019 Phase 3
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID